Search

COVID-19 raises profile, utility of digital therapeutic approaches in OA

COVID-19 RAISES PROFILE, UTILITY OF DIGITAL THERAPEUTIC APPROACHES IN OA

The COVID-19 pandemic forced the rheumatology community to adopt a number of telehealth and digital approaches in patient care, according...

'Personalized' use of platelet-rich plasma injections may be the future of OA treatment

'PERSONALIZED' USE OF PLATELET-RICH PLASMA INJECTIONS MAY BE THE FUTURE OF OA TREATMENT

Understanding the complex associations between pain, function and structural factors in the joints may allow clinicians to use intraarticular...

 
 
 
Osteoarthritis drug pipeline rattles as FDA rejects top contender: What comes next?

OSTEOARTHRITIS DRUG PIPELINE RATTLES AS FDA REJECTS TOP CONTENDER: WHAT COMES NEXT?

Progress toward effective drug therapies is often marked with failure; yet even among a host of difficult-to-treat arthritis conditions,...

Beta-blockers may reduce risk for knee osteoarthritis, hip/knee pain

BETA-BLOCKERS MAY REDUCE RISK FOR KNEE OSTEOARTHRITIS, HIP/KNEE PAIN

Common beta-blockers are associated with a reduced cumulative risk for knee osteoarthritis, knee pain and hip pain consultations, according...

 
 
 
Sprifermin may confer greater benefit to patients at risk for rapid knee OA progression

SPRIFERMIN MAY CONFER GREATER BENEFIT TO PATIENTS AT RISK FOR RAPID KNEE OA PROGRESSION

Sprifermin improved cartilage thickness and pain symptoms in a subgroup of patients with knee osteoarthritis who demonstrated low minimum...

NATURAL SUPPLEMENTS MAY IMPROVE SYMPTOMS OF KNEE OA

Published results showed use of natural supplements improved the symptoms of knee osteoarthritis and may be a safe and efficacious...

 
 
 

PFIZER/ELI LILLY'S ANTI-NGF OSTEOARTHRITIS DRUG WORKS, BUT FDA SAYS SAFETY RISKS ‘REMAINED CONCERNING'

Pfizer/Eli Lilly's anti-NGF osteoarthritis drug works, but FDA says safety risks ‘remained concerning' badams Mon, 03/22/2021 - 10:20

RESEARCHERS PROBE CELL NUCLEUS RESPONSE WITH NEEDLE-TIP TECHNIQUE

Kaitlin McCreery is the coauthor of a new paper published in Small that deals with diagnosing diseases such as osteoarthritis in soft...

 
 
 

STUDY FINDS POSITIVE SHORT-TERM RESULTS FROM SECOND-GENERATION PATELLOFEMORAL ARTHROPLASTY

For patients with isolated patellofemoral osteoarthritis, second-generation onlay patellofemoral arthroplasty showed safe and acceptable...

CAN YOU BE TOO OLD FOR HIP OR KNEE REPLACEMENT?

Today, people are enjoying longer lives - but joint pain from osteoarthritis persists and can interfere with an active lifestyle. That's...

 
 
 

KNOCKDOWN OF CIRC SLC39A8 PROTECTS AGAINST THE PROGRESSION OF OSTEOARTHRITIS BY REGULATING MIR-591/IRAK3 AXIS

Abstract Background The dysregulation of circular RNAs has been identified in various human diseases, including osteoarthritis. The...

INTENSE STRENGTH TRAINING DOES NOT EASE KNEE PAIN, STUDY FINDS

Millions of patients with knee osteoarthritis are told to exercise. A new study casts doubt on what sort of exercise is helpful.

 
 
 

SAFETY AND EFFICACY COMPARISON OF THREE- VS FOUR-NEEDLE TECHNIQUE IN THE MANAGEMENT OF MODERATE TO SEVERE OSTEOARTHRITIS OF THE KNEE USING COOLED RADIOFREQUENCY ABLATION

Abstract Purpose To analyze the safety and efficacy of image-guided genicular nerve cooled radiofrequency ablation for the treatment...

NSAIDs in Osteoarthritis: Study Suggests Need for New Look

NSAIDS IN OSTEOARTHRITIS: STUDY SUGGESTS NEED FOR NEW LOOK

Knee osteoarthritis patients using nonsteroidal anti-inflammatory drugs showed greater loss of medial minimum joint space width than...

 
 
 

IDENTIFICATION OF ABNORMALLY METHYLATED-DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS IN OSTEOARTHRITIS: A COMPREHENSIVE BIOINFORMATIC STUDY

Abstract Objectives To investigate abnormally methylated-differentially expressed genes and their related pathways in osteoarthritis...

GALAPAGOS' OSTEOARTHRITIS DRUG FLUNKS PHASE 2, DASHING HOPES OF $250M GILEAD DEAL

Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal ntaylor Fri, 10/16/2020 - 03:48

 
 
 

SORRENTO RELEASES POSITIVE RESULTS OF PHASE 1B TRIAL OF RESINIFERATOXIN IN REDUCTION OF OSTEOARTHRITIS KNEE PAIN

SAN DIEGO, Sept. 28, 2020 - Sorrento Therapeutics, Inc. released positive Phase 1b trial data of resiniferatoxin with completed Day...

Bio Roundup: SeaGen Scores, Dyne's Debut, Microbiome Moves & More

BIO ROUNDUP: SEAGEN SCORES, DYNE'S DEBUT, MICROBIOME MOVES & MORE

Gilead Sciences CEO Daniel O'Day has spoken openly about acquisitions as a way to build up the company's drug pipeline. This week,...

 
 
 
Unity Bio Restructuring Cuts 30% of Staff, Keeps Focus on Eye Drug

UNITY BIO RESTRUCTURING CUTS 30% OF STAFF, KEEPS FOCUS ON EYE DRUG

Unity Biotechnology is cutting nearly one third of its staff, a move that comes a month after the biotech's lead drug candidate failed...

MMP-13 ENZYME AND PH RESPONSIVE THERANOSTIC NANOPLATFORM FOR OSTEOARTHRITIS

Stimulus-responsive therapy permits precise control of therapeutic effect only at lesion of interest, which determines it a promising...